TITLE

Does Apolipoprotein E genotype affect cardiovascular risk in subjects with acromegaly?

AUTHOR(S)
Bozok Cetintas, Vildan; Zengi, Ayhan; Tetik, Asli; Karadeniz, Muammer; Ergonen, Faruk; Kucukaslan, Ali; Tamsel, Sadik; Kosova, Buket; Sahin, Serap; Saygılı, Fusun; Eroglu, Zuhal
PUB. DATE
June 2012
SOURCE
Endocrine (1355008X);Jun2012, Vol. 41 Issue 3, p465
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Acromegaly is a syndrome that results when the pituitary gland produces excess growth hormone after epiphyseal closure at puberty. Usually, subjects with acromegaly exhibit a 2- to 3-fold higher mortality rate from diseases that are associated with cardiovascular complications when compared to the normal population. In this study, we therefore aimed to evaluate whether a well-established cardiovascular risk factor, the Apolipoprotein E (Apo E) genotype, contributes to increased risk of cardiovascular complications in subjects with acromegaly. A total of 102 unrelated acromegaly subjects were prospectively included into this case-control association study and constituted our study group. The study group was comparable by age and gender with 200 unrelated healthy subjects constituting our control group. Genomic DNA was isolated from the peripheral blood leukocytes of all subjects and Apo E genotype (codon 112/158) was assessed by melting temperature analyses after using a real-time PCR protocol. The Apolipoprotein E4 allele was found at a significantly higher frequency in the study group when compared with the control group ( P = 0.032). Subjects with the E2 allele, on the other hand, had significantly increased values in body mass index ( P = 0.004), waist circumference ( P = 0.001), C-reactive protein (CRP) ( P < 0.001), and left-side carotid intima media thickness ( P = 0.025). The Apolipoprotein E2 genotype might contribute to increased risk of cardiovascular complications in subjects with acromegaly since it is concurrently present with other cardiovascular risk factors such as the left-side carotid intima media thickness and CRP.
ACCESSION #
74751787

 

Related Articles

  • BOX 10-1 DISORDERS OF GROWTH HORMONE. Scanlon, Valerie C.; Sanders, Tina // Essentials of Anatomy & Physiology;Jan2007, p230 

    Information on disorders of growth hormone from Chapter 10 of the book "Essentials of Anatomy & Physiology" is presented. It identifies the cause of pituitary dwarfism, gigantism and acromegaly. It reveals how pituitary dwarfism nay be reversed. It describes the physiological effects of...

  • Dental patient with acromegaly: a case report. Kashyap, Roopashri R.; Babu, Gogineni S.; Shetty, Shishir R. // Journal of Oral Science;Mar2011, Vol. 53 Issue 1, p133 

    Acromegaly is an acquired disorder related to excessive production of growth hormone after epiphyseal closure of bones. It is characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. The prevalence is estimated at...

  • acromegaly. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p14 

    An encyclopedia entry for "acromegaly" is presented. It refers to a disease characterized by abnormal enlargement of the jaw, the hands and feet, the skull, and also of the internal organs. The disease is caused by excessive secretion of growth hormone from the anterior pituitary gland at the...

  • Metastatic pituitary carcinoma in a patient with acromegaly: a case report. Sreenan, Seamus; Sengupta, Elizabeth; Tormey, William; Landau, Richard // Journal of Medical Case Reports;2012, Vol. 6 Issue 1, p322 

    Introduction: Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted either prolactin or adrenocorticotropic hormone, and another 24% were...

  • The PPAR-Gamma Activator Rosiglitazone Fails to Lower Plasma Growth Hormone and Insulin-Like Growth Factor-1 Levels in Patients with Acromegaly. Bastemir, Mehmet; Akin, Fulya; Yaylali, Guzin Fidan // Neuroendocrinology;Aug2007, Vol. 86 Issue 2, p119 

    Background/Aim: Despite combined therapy consisting of surgery, external X-ray, and medical therapy, a significant number of acromegaly patients continue to have uncontrolled growth hormone (GH) secretion and active disease. These patients, particularly those with large or invasive tumors,...

  • Surgery for acromegaly. Deopujari, C. E. // Neurology India;May/Jun2015, Vol. 63 Issue 3, p312 

    The author looks at the changing trends in the surgical management of acromegaly. Topics covered include the history of the different surgical approaches used to treat acromegaly, the role of tumor size and preoperative basal growth hormone levels in predicting treatment outcome, and the...

  • Pharmacological Therapy for Acromegaly: A Critical Review. Muller, Alex F.; van der Lely, Aart Jan // Drugs;2004, Vol. 64 Issue 16, p1817 

    The treatment of acromegaly has changed considerably over the last few decades. In the late 1970s, the introduction of the dopamine receptor agonists made it possible to reduce growth hormone (GH) secretion by somatotropinomas for the first time. Thereafter, the introduction of the somatostatin...

  • Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Chanson, Philippe // Neuroendocrinology;Feb2016, Vol. 103 Issue 1, p50 

    Treatment of acromegaly aims to correct (or prevent) tumor compression of surrounding tissues by excising the disease-causing lesion and reduce growth hormone (GH) and IGF-1 levels to normal values. When surgery (the usual first-line treatment) fails to correct GH/IGF-1 hypersecretion, medical...

  • Transsphenoidal Microsurgery for Newly Diagnosed Acromegaly: A Personal View after More than 1,000 Operations. Lüdecke, Dieter K.; Abe, Takumi // Neuroendocrinology;2006, Vol. 83 Issue 3/4, p230 

    The aim of this short review is to inform about the possibilities and limits of transnasal microsurgery in acromegaly. The current reports on surgical remissions, according to the strict criteria with international consensus using age- and sex-related normal levels for insulin-like growth...

  • Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Adelman, Daphne T.; Liebert, Karen J. P.; Nachtigall, Lisa B.; Lamerson, Michele; Bakker, Bert // International Journal of General Medicine;2013, Vol. 6, p31 

    Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics